Mifepristone implementation in primary care: Clinician and staff insights from a pilot learning collaborative.

Abortion Learning collaborative Mifepristone Miscarriage management Primary care

Journal

Contraception
ISSN: 1879-0518
Titre abrégé: Contraception
Pays: United States
ID NLM: 0234361

Informations de publication

Date de publication:
11 Sep 2023
Historique:
received: 24 04 2023
revised: 06 09 2023
accepted: 08 09 2023
pubmed: 14 9 2023
medline: 14 9 2023
entrez: 13 9 2023
Statut: aheadofprint

Résumé

The ExPAND Mifepristone (ExPAND) learning collaborative aims to support primary care providers in overcoming logistical barriers to mifepristone provision. This qualitative study describes clinician and staff perspectives on the impact of ExPAND in two federally qualified health center networks (FQHCs). Researchers conducted semi-structured qualitative interview with a purposive sample of clinicians, staff, and leadership from two Illinois FQHCs. We analyzed transcripts in batches using modified grounded theory to identify themes regarding the reception of ExPAND and barriers to and facilitators of mifepristone implementation. Participants (n = 13) expressed strong support for providing mifepristone for miscarriage management at their clinics. Most also personally supported mifepristone for abortion care. Many participants felt that ExPAND reflected their clinics' values, as it strengthens the primary care relationship, emphasizes patient-centered care, and addresses disparities in access. Barriers to implementation included fear that providing abortion care would jeopardize FQHC funding and logistical hurdles due to the coronavirus disease pandemic. Participants felt that mifepristone provision in primary care was an important service, and that ExPAND helped achieve that goal. Future clinics participating in ExPAND would benefit from education about how FQHCs can provide mifepristone for abortion care while complying with federal funding restrictions. Learning collaboratives like ExPAND can prepare primary care clinics to provide mifepristone. Participants describe a clear benefit of mifepristone integration to their patients, and they report mifepristone integration aligns with clinic values.

Identifiants

pubmed: 37704043
pii: S0010-7824(23)00378-5
doi: 10.1016/j.contraception.2023.110280
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

110280

Informations de copyright

Copyright © 2023. Published by Elsevier Inc.

Auteurs

Meera Sakthivel (M)

Pritzker School of Medicine, University of Chicago, Chicago, IL, United States.

Hillary Wolff (H)

Department of Family Medicine, University of Chicago Medicine, Chicago, IL, United States.

Kristie Monast (K)

KM Consulting & Training, Boston, MA, United States.

Ashley McHugh (A)

Department of Family Medicine, University of Chicago Medicine, Chicago, IL, United States.

Debra Stulberg (D)

Department of Family Medicine, University of Chicago Medicine, Chicago, IL, United States.

Elizabeth Janiak (E)

Department of Obstetrics and Gynecology, Brigham and Women's Hospital, Boston, MA, United States; Harvard Medical School, Boston, MA, United States; Department of Social and Behavioral Sciences, Harvard TH Chan School of Public Health, Boston, MA, United States. Electronic address: ejaniak@bwh.harvard.edu.

Classifications MeSH